1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Vaccine Will Be 'Affordable And Globally Available'

 
• By Andrew McConaghie

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.

Doctor's hand holding bottle vaccine Covid-19 from storage box. Medication treatment concept.
Three COVID-19 vaccines have now shown positive Phase III results • Source: Shutterstock

Following the promising results from trials of the COVID-19 vaccine developed by AstraZeneca PLC and the University of Oxford, the UK company says it will now prepare regulatory submissions around the world, which could result in the vaccine being granted emergency use authorization before the end of the year.

The first interim analysis of the Phase III data showed that AZD1222 achieved a 70% efficacy rate, while an "intriguing" signal suggested that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By Leela Barham

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.

Non-Submissions To England’s NICE Surge Across All Disease Areas

 
• By Leela Barham

Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.

More from Europe